Background: Polysubstance use (PSU) is common among patients with cannabis use (CU) and is related to more severe CU problems. However, it is unclear how PSU predicts CU treatment outcomes beyond CU patterns. We examined the frequency, amount, and class of additionally used substances as predictors for primary and secondary outcomes. Methods: We conducted crude and adjusted regression analyses for PSU variables as predictors of remission, abstinence, -reduction, and secondary outcomes in 166 help-seeking -patients from a randomized clinical trial of CANDIS, a -cognitive behavioral treatment program. Results: Patients with recent illegal PSU experienced more difficulties in reducing their CU (B = –1.22, p < 0.001). In contrast, remission rates were slightly higher in patients with a wide variety of -last-year-PSU (RD = 0.04, p < 0.001). Amphetamine use -predicted poorer outcomes regarding CU-related problems (B = –4.22, p = 0.019), and the use of opiates, inhalants, and dissociative substances predicted poorer physical health outcomes (B = –0.62, p = 0.009; B = –0.96, p = 0.039; B = –1.18, p = 0.007). Conclusions: CU treatment is also effective for patients with moderate PSU. However, treatment effects may be enhanced by addressing specific PSU characteristics as part of a modularized program.

EMCDDA: European Drug Report 2017: Trends and Developments. Lisbon, EMCDDA, 2017.
Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L: Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev 2016; 5:CD005336.
Cooper K, Chatters R, Kaltenthaler E, Wong R: Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. Health Technol Assess 2015; 19: 1–130.
Chatters R, Cooper K, Day E, Knight M, Lagundoye O, Wong R, Kaltenthaler E: Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review. Addict Res Theory 2016; 24: 93–110.
EMCDDA: Treatment of Cannabis-Related Disorders in Europe. Lisbon, European Monitoring Centre for Drugs and Drug Addiction, 2015.
World Health Organization: ICD-10 Classifications of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines. Geneva, 2000.
Barrett SP, Darredeau C, Pihl RO: Patterns of simultaneous polysubstance use in drug using university students. Hum Psychopharmacol 2006; 21: 255–263.
Connor JP, Gullo MJ, Chan G, Young RM, Hall WD, Feeney GF: Polysubstance use in cannabis users referred for treatment: drug use profiles, psychiatric comorbidity and cannabis-related beliefs. Front Psychiatry 2013; 4: 79.
EMCDDA: Polydrug Use: Patterns and Responses, Selected Issue. Lisbon, EMCDDA, 2009.
Chen K, Kandel DB: Predictors of cessation of marijuana use: an event history analysis. Drug Alcohol Depend 1998; 50: 109–121.
Patton GC, Coffey C, Lynskey MT, Reid S, Hemphill S, Carlin JB, Hall W: Trajectories of adolescent alcohol and cannabis use into young adulthood. Addiction 2007; 102: 607–615.
Perkonigg A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R, Wittchen HU: The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction 2008; 103: 439–449.
Bovasso GB: Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001; 158: 2033–2037.
von Sydow K, Lieb R, Pfister H, Höfler M, Wittchen HU: What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. Drug Alcohol Depend 2002; 68: 49–64.
Wittchen HU, Behrendt S, Hofler M, Perkonigg A, Rehm J, Lieb R, Beesdo K: A typology of cannabis-related problems among ­individuals with repeated illegal drug use in the first three decades of life: evidence for heterogeneity and different treatment needs. Drug Alcohol Depend 2009; 102: 151–157.
Davis ML, Powers MB, Handelsman P, Medina JL, Zvolensky M, Smits JA: Behavioral therapies for treatment-seeking cannabis users: a meta-analysis of randomized controlled trials. Eval Health Prof 2015; 38: 94–114.
Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW: A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008; 165: 179–187.
EMCDDA: 2014 Annual Report on the State of the Drugs Problem in Europe. Lisbon, EMCDDA, 2014.
Kraemer HC, Kazdin AE, Offord DR, Kessler RC, Jensen PS, Kupfer DJ: Coming to terms with the terms of risk. Arch Gen Psychiatry 1997; 54: 337–343.
Hoch E, Noack R, Henker J, Pixa A, Höfler M, Behrendt S, Bühringer G, Wittchen HU: Efficacy of a targeted cognitive-behavioral treatment program for cannabis use disorders (CANDIS). Eur Neuropsychopharmacol 2012; 22: 267–280.
Hoch E, Bühringer G, Pixa A, Dittmer K, Henker J, Seifert A, Wittchen HU: CANDIS treatment program for cannabis use disorders: findings from a randomized multi-site translational trial. Drug Alcohol Depend 2014; 134: 185–193.
Hoch E: CANDIS. A Marijuana Treatment Program for Youth and Adults. Hazelden, 2017.
Hoch E, Rohrbacher H: Chapter 19 – CANDIS program: modular treatment of cannabis use disorders A2; in Preedy VR (ed): Handbook of Cannabis and Related Pathologies. San Diego, Academic Press, 2017, pp e193–e201.
Mental Health Gap Action Programme: Psychosocial Interventions for the Management of Cannabis Dependence, WHO Mental Health Gap Action Programme, 2015.
Hoch E, Bühringer G, Henker J, Rohrbacher H, Noack R, Pixa A, Dittmer K, Rühlmann A, Wittchen HU: Untersuchungskonzept für die CANDIS (CANnabis DISorders)-Studie zur Behandlung von cannabisbezogenen Störungen: Ein Beispiel translationaler Forschung. SUCHT 2011; 57: 183–192.
Wittchen HU, Pfister H: DIA-X-Interviews: Manual für Screening Verfahren und Interview; Interviewheft Längsschnittuntersuchung (DIA-X-Lifetime); Ergänzungsheft (DIA-X-Lifetime); Interviewheft Querschnittsuntersuchung (DIA-X-12 Monate); Ergänzungsheft (DIA-X-12 Monate); PC-Programm zur Durchführung des Interviews (Längs- und Querschnittsuntersuchung); Auswertungsprogramm. Frankfurt, 1997.
Sobell LC, Sobell MB: Timeline follow back: a technique for addressing self-reported alcohol consumption; in Litten RZ, Allen J (eds): Measuring Alcohol Consumption Psychological and Biological Methods. New Jersey, Humana Press, 1992, pp 41–72.
Körkel J, Schindler C: Zielskala. Evangelische Hochschule Nürnberg, 1998.
World Health Organization: ICD-10 Classifications of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines. Geneva, World Health Organisation, 1992.
Bashford J, Flett R, Copeland J: The cannabis use problems identification test (CUPIT): development, reliability, concurrent and predictive validity among adolescents and adults. Addiction 2010; 105: 615–625.
Herrman H, Metelko Z, Szabo S, Rajkumar S, Kumar S, Vanheck G, Devries J, Sucre A, Kabanov, Lomachenkov, Burkovsky, Sukwatana S, Meesapya K, Skevington S, Patrick D, Martin M, Mutambirwa J, Sartorius N, Orley J, Kuyken W: Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res 1993; 2: 153–159.
Royall RM: Model robust confidence intervals using maximum likelihood estimators. Int Stat Rev 1986; 54: 221–226.
Brouette T, Anton R: Clinical review of inhalants. Am J Addict 2001; 10: 79–94.
Reed BJF, May PA: Inhalant abuse and juvenile delinquency: a control study in Albuquerque, New Mexico. Int J Addict 1984; 19: 789–803.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.